Vmbook Online ordering

Icons

**Company Overview**

**Name:** Icon PLC

**Stock Symbol:** ICN (NYSE)

**Industry:** Engineering and Construction

**Headquarters:** Dublin, Ireland

**Business Description**

Icon is a global engineering and construction company that provides services to the pharmaceutical, biotechnology, and semiconductor industries. The company specializes in the design, construction, and validation of complex facilities for the production of drugs, biologics, and medical devices.

**Key Financial Metrics**

* **Revenue:** $1.5 billion (2021)

* **Net Income:** $140 million (2021)

* **Earnings Per Share (EPS):** $0.70 (2021)

* **Market Capitalization:** $4.5 billion (as of May 2023)

**Growth and Earnings**

Icon has consistently reported strong growth in recent years, driven by increasing demand for its services in the pharmaceutical and biotechnology sectors. The company has also benefited from a number of strategic acquisitions.

* **Revenue Growth:** 15% CAGR (2017-2021)

* **EPS Growth:** 20% CAGR (2017-2021)

* **Earnings Forecast:** Analysts expect Icon to continue to grow its earnings in the coming years, with EPS projected to reach $0.90 in 2023.

**Valuation**

Icon trades at a forward price-to-earnings (P/E) ratio of approximately 25x, which is in line with industry peers. The company's strong growth prospects and solid financial performance make it an attractive investment for long-term investors.

**Key Risks**

* **Competition:** Icon faces competition from a number of large and established engineering and construction companies.

* **Project Delays:** The construction of complex facilities can be subject to delays, which can impact Icon's revenue and profitability.

* **Regulatory Changes:** The pharmaceutical and biotechnology industries are heavily regulated, and changes in regulations could affect Icon's business.

**Conclusion**

Icon is a well-established and growing engineering and construction company with a strong track record of financial performance. The company's focus on the pharmaceutical and biotechnology sectors positions it well for continued growth in the coming years. Investors should consider Icon as a potential investment for their portfolios.